Anubis Barcelona Concentrate
NDC Package 83021-839-07
Package Information
Anubis Barcelona (propanediol, glycerin, magnesium ascorbyl phosphate) concentrates is classified as a
- allergens - [cs]
- allergens - [cs]
- ammonium ion binding activity - [moa] (mechanism of action)
- anti-coagulant - [epc] (established pharmacologic class)
- calcium chelating activity - [moa] (mechanism of action)
- cell-mediated immunity - [pe] (physiologic effect)
- decreased coagulation factor activity - [pe] (physiologic effect)
- glycerol - [cs]
- increased histamine release - [pe] (physiologic effect)
- increased igg production - [pe] (physiologic effect)
- lead chelating activity - [moa] (mechanism of action)
- lead chelator - [epc] (established pharmacologic class)
- nitrogen binding agent - [epc] (established pharmacologic class)
- non-standardized chemical allergen - [epc] (established pharmacologic class)
- pediculicide - [epc] (established pharmacologic class)
- standardized chemical allergen - [epc] (established pharmacologic class)
Identification & Billing
Clinical Specifications
- BENZOIC ACID .0009 g/1.5mL
- BENZYL ALCOHOL .01215 g/1.5mL
- DEHYDROACETIC ACID .00135 g/1.5mL
- EDETIC ACID .000009 g/1.5mL
- FRAGRANCE 13576 .00285 g/1.5mL
- GLYCERIN .01035 g/1.5mL
- HYDROXYCITRONELLAL .00006 g/1.5mL
- ISOMETHYL-.ALPHA.-IONONE .00003 g/1.5mL
- PEG-8 CAPRYLIC/CAPRIC GLYCERIDES .15 g/1.5mL
- PHENOXYETHANOL .0003 g/1.5mL
- PROPANEDIOL .15 g/1.5mL
- SORBIC ACID .0006 g/1.5mL
- WATER 1.16659425 mL/1.5mL
- Allergens - [CS]
- Allergens - [CS]
- Ammonium Ion Binding Activity - [MoA] (Mechanism of Action)
- Anti-coagulant - [EPC] (Established Pharmacologic Class)
- Calcium Chelating Activity - [MoA] (Mechanism of Action)
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Glycerol - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased IgG Production - [PE] (Physiologic Effect)
- Lead Chelating Activity - [MoA] (Mechanism of Action)
- Lead Chelator - [EPC] (Established Pharmacologic Class)
- Nitrogen Binding Agent - [EPC] (Established Pharmacologic Class)
- Non-Standardized Chemical Allergen - [EPC] (Established Pharmacologic Class)
- Pediculicide - [EPC] (Established Pharmacologic Class)
- Standardized Chemical Allergen - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 83021 - Anubis Cosmetics Sl
- 83021-839 - Anubis Barcelona
- 83021-839-07 - 1.5 mL in 1 VIAL, SINGLE-USE
- 83021-839 - Anubis Barcelona
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83021-839-07 identifies a specific commercial package of 1.5 ml in 1 vial, single-use of Anubis Barcelona, a human over the counter drug labeled by Anubis Cosmetics Sl. This concentrate is formulated for topical use and contains benzoic acid; benzyl alcohol; dehydroacetic acid; edetic acid; fragrance 13576; glycerin; hydroxycitronellal; isomethyl-.alpha.-ionone; peg-8 caprylic/capric glycerides; phenoxyethanol; propanediol; sorbic acid; water as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Anubis Cosmetics Sl on October 18, 2022.
How is this Anubis Cosmetics Sl product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83021083907. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.